

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations
ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS Company name: Prilenia Therapeutics*
Website: <https://www.prilenia.com>* CEO name: Dr. Michael R. Hayden* Select a CATEGORY:
Biotech/Pharma* Select up to two SESSIONS per abstract from the list below * 2. Do we Know
Enough About the Brain to Treat Neurological Disorders? o Executive Summary / Investment Rational
Prilenia Therapeutics is a clinical stage biotech company committed to improving lives of patients and
their families by developing treatments for neurodegenerative and neurodevelopmental disorders.
Prilenia is led by Michael Hayden, MBChB, PhD., a world-renowned scientist in Huntington Disease
(HD) research. The company has raised \$144M thus far and is backed by a group of well-respected
life-science investors. o Core Technology Pridopidine, is a novel, highly selective and potent Sigma-1
Receptor (S1R) agonist, demonstrating neuroprotective effects in numerous models of
neurodegenerative diseases. Pridopidine is an orally administered small molecule with an established
safety profile in >1300 subjects. It is the only S1R agonist in development for HD and ALS, and the
only drug candidate currently in phase 3 for HD. o Product Profile/Pipeline Pridopidine is under
evaluation for HD in the Phase 3 PROOF-HD trial with expected top line data (Q2 2023) to be
presented. In ALS, pridopidine was selected for the Phase 2 HEALEY ALS Platform Trial and
demonstrated potential beneficial effects on measures of disease progression including, speech,
respiratory and bulbar function, that support further clinical development (Phase 3). In pre-clinical
studies, pridopidine has shown potential in additional neurodegenerative and neurodevelopment
disorders. o Business Strategy Prilenia will pursue regulatory approval of pridopidine for the
treatment of HD upon positive phase 3 results. We are actively preparing for a potential first launch
of pridopidine in the US in 2024. Prilenia plans to continue building the team to forward integrate in
key markets and partner in other regions. o What's Next? Prilenia plans to evaluate pridopidine in
prodromal HD and Juvenile HD, and will continue to expand its pipeline pursuing additional
indications including Wolfram Syndrome, Rett Syndrome, Fragile X, neurodegenerative eye diseases,
Alzheimer's Disease, and Parkinson's Disease. Prilenia is preparing for additional financing (including
the potential to access the capital markets) post-positive readout, to support commercial launch,
market build-up and pipeline expansion.